(34), it was demonstrated that the expression SLFN5 is known to enhance cellular motility and aggressiveness of glioblastoma cells, and elevated SLFN5 expression is significantly correlated with the presence of high-grade gliomas and poor patient survival, thereby driving the malignancy of the disease. The gene discussed is SLFN5; the disease is central nervous system cancer.